Barrett's esophagus: proton pump inhibitors and chemoprevention I

Triadafilopoulos, G.; Taddei, Antonio; Bechi, Paolo; Freschi, Giancarlo; Ringressi, Maria Novella; Degli'Innocenti, D. R.; Castiglione, Francesca; Masini, Emanuela; Majewski, M.; Wallner, G.; Sarosiek, J.; Dillon, J. F.; Mccallum, R. C.; Dvorak, K.; Goldman, A.; Woodland, P.; Sifrim, D.; Richter, J. E.; Vieth, M.; Neumann, H.; Langner, C.; Ishimura, N.; Amano, Y.; Felix, V. N.

doi:10.1111/j.1749-6632.2011.06047.x

The following on proton pump inhibitors and chemoprevention in Barrett's esophagus includes commentaries on normalization of esophageal refluxate; the effects of 5-HT(4) agonists on EGF secretion and of lubripristone on chloride channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association Probability in the evaluation of potential response to treatment.

Barrett's esophagus: proton pump inhibitors and chemoprevention I / G. Triadafilopoulos, A. Taddei, P. Bechi, G. Freschi, M. N. Ringressi, D. R. Degli'Innocenti, F. Castiglione, E. Masini, M. Majewski, G. Wallner, J. Sarosiek, J. F. Dillon, R. C. McCallum, K. Dvorak, A. Goldman, P. Woodland, D. Sifrim, J. E. Richter, M. Vieth, H. Neumann, et al.. - In: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. - ISSN 1749-6632. - ELETTRONICO. - 1232:(2011), pp. 93-113. [10.1111/j.1749-6632.2011.06047.x]